ULTRA LONG: BioFreedom Ultra

Launched by BIOSENSORS EUROPE SA · Dec 7, 2022

Keywords

ClinConnect Summary

The ULTRA LONG: BioFreedom Ultra trial is studying a new type of heart stent called the BioFreedom Ultra, which is designed for patients with coronary artery disease who are at a high risk of bleeding. The main goal of the trial is to see if the new sizes of this stent are as safe and effective as the sizes that have already been approved for use. This study is currently looking for participants who are at least 18 years old and have been diagnosed with conditions like unstable angina or a recent heart attack. To qualify, they also need to have a life expectancy of over one year and meet certain criteria indicating they are at high risk for bleeding.

Participants in this study can expect to undergo a procedure to insert the stent into their heart and will need to take specific medications called dual anti-platelet therapy for one month afterward to help prevent blood clots. The study is open to all genders, and participants will be monitored for their safety and the stent's performance. It’s important to note that some patients, such as those who are pregnant or have certain medical conditions, may not be eligible to join the trial.

Gender

ALL

Eligibility criteria

• Clinical:
• • 1. Patients at high bleeding risk (HBR) with an indication for PCI. This includes subjects with chronic coronary syndrome, unstable angina, or non-ST elevation myocardial infarction.
• • 2. Patients must provide written informed consent
• • 3. Patient is at least 18 years old
• • 4. Patients with a life expectancy of \> 1 year at time of consent
• 5. HBR patients defined according to the ARC-HBR criteria and suitable to receive dual anti platelet therapy (DAPT) for one month. To be qualified HBR, patients have to have at least 1 major and/or 2 minor criteria defined as follow:
• • Major Minor Age ≥75 years old Anticipated use of long-term oral anticoagulation\* Severe or end-stage CKD (eGFR \<30 mL/min) Moderate CKD (eGFR 30-59 mL/min) Hemoglobin \<11 g/dL Hemoglobin 11-12.9 g/dL for men and 11-11.9 g/dL for women Spontaneous bleeding requiring hospitalization or transfusion in the past 6 months or at any time, if recurrent Spontaneous bleeding requiring hospitalization or transfusion within the past 12 months not meeting the major criterion Moderate or severe baseline thrombocytopenia† (platelet count \<100×109/L) Chronic bleeding diathesis Liver cirrhosis with portal hypertension Long-term use of oral NSAIDs or steroids Active malignancy‡ (excluding non-melanoma skin cancer) within the past 12 months Previous spontaneous ICH (at any time) Previous traumatic ICH within the past 12 months Presence of a bAVM Moderate or severe ischemic stroke§ within the past 6 months Any ischemic stroke at any time not meeting the major criterion Nondeferrable major surgery on DAPT Recent major surgery or major trauma within 30 days before PCI bAVM indicates brain arteriovenous malformation; CKD, chronic kidney disease; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; HBR, high bleeding risk; ICH, intracranial hemorrhage; NSAID, nonsteroidal anti-inflammatory drug; and PCI, percutaneous coronary intervention.
• • \*This excludes vascular protection doses.
• • †Baseline thrombocytopenia is defined as thrombocytopenia before PCI.
• • ‡Active malignancy is defined as diagnosis within 12 months and/or ongoing requirement for treatment (including surgery, chemotherapy, or radiotherapy).
• • §National Institutes of Health Stroke Scale score ≥5.
• Angiographic:
• • 6. Patients scheduled to undergo PCI of a de novo lesion (no in-stent restenosis) with reference vessel diameter and lesion length suitable for treatment with at least one study device
• Exclusion Criteria:
• • 1. Pregnant and breastfeeding women
• • 2. Patients lacking capacity (i.e. patients suffering from dementia and others) to provide informed consent
• • 3. Patients not expected to comply with 1 month of DAPT
• • 4. Staged procedures in the target vessel
• • 5. Active bleeding at the time of inclusion
• • 6. Cardiogenic shock
• • 7. Unlikely compliance with long-term single anti-platelet therapy
• • 8. Known hypersensitivity or contraindication to aspirin, clopidogrel (or to any other P2Y12 inhibitor if applicable), cobalt chromium, zinc, Biolimus A9 or a sensitivity to contrast media, which cannot be adequately pre-medicated
• • 9. Currently participating in another trial before reaching primary endpoint
• • 10. Patients under judicial protection, tutorship or curatorship (France only)

Trial Officials